Quest Diagnostics Inc vs Redwire Corporation — how do they compare? Quest Diagnostics Inc trades at $230.17 (market cap $25.48B), while Redwire Corporation trades at $9.92 (market cap $2.44B). The key difference: Quest Diagnostics Inc is far larger — about 10.4× Redwire Corporation's market cap, and Quest Diagnostics Inc pays a 1.49% dividend while Redwire Corporation pays none. Which is the better fit depends on your goals — on Pluang, investors hold Quest Diagnostics Inc for 56 Days and Redwire Corporation for 18 Days on average.
| DGX | RDW | |
|---|---|---|
Market Cap | $25.48B | $2.44B |
Volume | 941,866 | 11,053,212 |
Sector | Health | Industrials |
52-Week High | $247.45 | $25.90 |
52-Week Low | $173.49 | $5.06 |
Typical Hold Time | 56 Days | 18 Days |
Enterprise Value | $31.23B | $1.97B |
Dividend Yield | 1.49% | — |
Signals from Pluang's Aura AI — not financial advice
Quest Diagnostics (DGX) trades at $227.00, down 0.64% with a bearish technical signal. The company shows strong fundamentals with three consecutive quarterly earnings beats and revenue growth from $9.9B in 2024 to $11.0B in 2025. Recent developments include positive clinical study results and a new Apple Health integration, though Medicare reimbursement cuts pose headwinds. The stock trades near support at $226 with oversold RSI readings suggesting potential for near-term bounce.
DGX presents a mixed outlook with solid execution offset by regulatory risks. The 10% upside to consensus price target of $250 offers opportunity, but Medicare payment reductions and rising debt levels require monitoring. Recent earnings momentum and strategic partnerships support growth, making DGX suitable for investors comfortable with healthcare sector volatility.
Redwire Corporation (RDW) trades at $10.24, down 3.58% today, with bearish technical signals despite strong analyst support. The company shows robust revenue growth with $335 million in 2025 and projected $426 million in 2026, though profitability remains challenged with negative net margins. Recent Space Force contract wins and partnerships position RDW in the expanding space infrastructure market, but cash flow concerns persist with negative operating cash flow.
RDW presents a high-risk growth opportunity with 80% analyst buy ratings and a $14.88 consensus target offering 45% upside. However, persistent losses, negative cash flow, and dependence on SpaceX's Starship success create significant volatility. The stock suits aggressive investors betting on space infrastructure growth despite current financial challenges.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.
Read more on DGX →Redwire Corporation is a pure-play space infrastructure company that provides a wide range of advanced solutions for the next generation of space exploration and utilization. The company's capabilities span critical space technology, including on-orbit servicing, satellite components, space robotics, and digital engineering. Redwire's products and services are used by civil, commercial, and national security customers to enable missions from low Earth orbit to deep space.
Read more on RDW →